Intranasal cannabinoid developer Therapix Biosciences has announced the appointment of its Chairman of the Board Ascher Shmulewitz as interim CEO. In May 2017, the company said that it was looking for a US-based CEO after Elran Haber stepped down from the role.
Therapix licensed an intranasal cannabinoid formulation from Hebrew University’s technology transfer company Yissum in 2016 and earlier this year licensed Hebrew University intranasal delivery technology.
The company is developing both intranasal and sublingual dronabinol formulations, with clinical programs focused on Tourette Syndrome, mild cognitive impairment, and traumatic brain injury.
Shmulewitz commented, “I am pleased by the decision of the board and shareholders to appoint me as Interim CEO and I look forward to the opportunities ahead. I believe that this company’s strong portfolio of therapeutic candidates for unmet needs is promising.”
Read the Therapix Biosciences press release.
